Clinical trial · Interventional
Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
NCT07427537CI-TRIAL-00103840miR-CIPN#1recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Colon Neoplasm | Colon Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neuropathy;Peripheral | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Assessment of blood concentrations of microRNAs | Diagnostic Test | — | UNRESOLVED |
| Assessment of blood concentrations of neurofilament light chain | Diagnostic Test | — | UNRESOLVED |
| Chemotherapy-induced peripheral neuropathy (CIPN) - grade | Other | — | UNRESOLVED |
| Chemotherapy-induced peripheral neuropathy (CIPN) - severity | Other | — | UNRESOLVED |
| Neuropathic pain assessment | Other | — | UNRESOLVED |
| Pain assessement | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Paclitaxel group
- description
- Patients suffering from lung cancer and treated with paclitaxel
- interventionNames
- Diagnostic Test: Assessment of blood concentrations of microRNAs
- Other: Chemotherapy-induced peripheral neuropathy (CIPN) - grade
- Other: Pain assessement
- Diagnostic Test: Assessment of blood concentrations of neurofilament light chain
- Other: Neuropathic pain assessment
- Other: Chemotherapy-induced peripheral neuropathy (CIPN) - severity
- type
- EXPERIMENTAL
- label
- Oxaliplatin group
- description
- Patients suffering from colorectal cancer and treated with oxaliplatin
- interventionNames
- Diagnostic Test: Assessment of blood concentrations of microRNAs
- Other: Chemotherapy-induced peripheral neuropathy (CIPN) - grade
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or * Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles. Exclusion Criteria: * Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.), * History of stroke, * Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100), * Pain (NRS ≥ 4/10), * Pregnant or breastfeeding women, * Patients under guardianship, curatorship, deprived of liberty, or under legal protection
References
Publications (0)
Data not yet available
No reference posted for this study.